Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney risks, holds significant promise for volume growth as it becomes more ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.

By introducing Empagliflozin at INR 5.49 per tablet for ... API raw material which is DMF grade,” he informed. The kind of, molecule, the API when we export is being used, the same has been ...

Jardiance is also authorised to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. According to the FDA, heart disease impacts more than ...

Empagliflozin improved clinical outcomes in patients with acute heart failure (AHF), regardless of blood pressure (BP) levels, with particularly strong benefits observed in those with diastolic BP ...

Before the entry of generics, Jardiance was priced at ₹58 ... Our advanced R&D ensures the same efficacy as the innovator molecule at a fraction of the cost," said Alok Malik, President ...

The kind of, molecule, the API when we export is being ... will not be changed but new patients, would be given Empagliflozin. That’s a kind of an assumption we make. On the basis of that ...